Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Pediatric Fabry disease.

Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R.

Pediatrics. 2005 Mar;115(3):e344-55. Epub 2005 Feb 15.

PMID:
15713906
2.

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO.

Muscle Nerve. 2003 Dec;28(6):703-10.

PMID:
14639584
3.

Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.

Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR.

Pediatr Res. 2008 Nov;64(5):550-5. doi: 10.1203/PDR.0b013e318183f132.

PMID:
18596579
4.

Anderson-Fabry disease: a multiorgan disease.

Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G.

Curr Pharm Des. 2013;19(33):5974-96. Review.

PMID:
23448451
5.

Fabry disease: treatment and diagnosis.

Rozenfeld PA.

IUBMB Life. 2009 Nov;61(11):1043-50. doi: 10.1002/iub.257.

6.

Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys.

Cybulla M, Schaefer E, Wendt S, Ling H, Kröber SM, Hövelborn U, Schandelmaier S, Rohrbach R, Neumann HP.

Am J Kidney Dis. 2005 May;45(5):e82-9.

PMID:
15861341
7.

[Evaluation of patients with Fabry disease in Argentina].

AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales).

Medicina (B Aires). 2010;70(1):37-43. Spanish.

PMID:
20228022
8.

Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.

Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C; Fabry Registry.

Nephrol Dial Transplant. 2008 May;23(5):1600-7. doi: 10.1093/ndt/gfm848. Epub 2008 Jan 5.

PMID:
18175781
9.

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB.

Heart. 2008 Feb;94(2):153-8. Epub 2007 May 4.

PMID:
17483124
10.
11.

An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, et al.

N Engl J Med. 1995 Aug 3;333(5):288-93.

12.

Cardiac manifestations of Anderson-Fabry disease in children and adolescents.

Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M.

Acta Paediatr. 2008 Apr;97(4):463-9. doi: 10.1111/j.1651-2227.2008.00700.x.

PMID:
18363956
13.

Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.

Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW.

Circulation. 2009 May 19;119(19):2561-7. doi: 10.1161/CIRCULATIONAHA.108.841494. Epub 2009 May 4.

14.

Treatment of fabry disease: current and emerging strategies.

Rozenfeld P, Neumann PM.

Curr Pharm Biotechnol. 2011 Jun;12(6):916-22. doi: 1389-2010/11 $58.00+.00. Review.

PMID:
21235448
15.

Clinical spectrum of Anderson Fabry disease in a Romanian family.

Tudor A, Muşat A, Doscan A, Bari M, Zapucioiu C, Urdea E, Cochior D, Peţa D.

Rom J Intern Med. 2006;44(2):201-10.

PMID:
17236300
16.

Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.

Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, Sá-Miranda MC.

Neurobiol Dis. 2009 Jan;33(1):48-56. doi: 10.1016/j.nbd.2008.09.001. Epub 2008 Sep 23.

PMID:
18848893
17.

The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.

Weidemann F, Breunig F, Beer M, Sandstede J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM.

Eur Heart J. 2005 Jun;26(12):1221-7. Epub 2005 Feb 23.

PMID:
15728649
18.

Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.

Przybylska M, Wu IH, Zhao H, Ziegler RJ, Tousignant JD, Desnick RJ, Scheule RK, Cheng SH, Yew NS.

J Gene Med. 2004 Jan;6(1):85-92.

PMID:
14716680
19.

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J.

Circulation. 2009 Feb 3;119(4):524-9. doi: 10.1161/CIRCULATIONAHA.108.794529. Epub 2009 Jan 19.

20.

Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study.

Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Yoshimitsu M, Higuchi K, Nakao S, Anan R, Minagoe S, Tei C.

J Cardiol. 2008 Feb;51(1):50-9. doi: 10.1016/j.jjcc.2007.12.001. Epub 2008 Feb 6.

Supplemental Content

Support Center